To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Zadaxin (Thymalfasin) Approved For Hepatitis C In Mexico, Peru, Sri Lanka URL: http://www.pslgroup.com/dg/1E294A.htm Doctor's Guide September 28, 2000
SAN MATEO, CA -- September 28, 2000 -- SciClone Pharmaceuticals announced that it has received an issued patent in Mexico for the use of the Company's lead drug, Zadaxin (thymalfasin), for the treatment of hepatitis C. SciClone also announced that Peru has expanded Zadaxin's approval to include the treatment of hepatitis C as well as the previously approved hepatitis B. In Latin America, Zadaxin is approved for sale in Mexico, Peru, Argentina and Venezuela. Approved indications include hepatitis B, hepatitis C and as a viral vaccine adjuvant for patients with weakened immune systems. "The Mexican hepatitis C patent is of particular significance as Mexico is our first North American market and clearly one of the most important Latin American market," said Donald R. Sellers, SciClone's President and Chief Executive Officer. "Our Zadaxin launch in Mexico is in full swing." Sellers noted that SciClone will be a major participant at the 16th Latin American Congress of Hepatology held this year in Mexico throughout the first week of October. The upcoming congress will be the Company's most significant medical education opportunity to date with Latin American physicians, researchers and hepatitis opinion leaders. SciClone also announced that Zadaxin approval has been expanded from hepatitis B to include hepatitis C in Sri Lanka. Zadaxin is approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. Related Links: Zadaxin (thymalfasin) and SciClone Pharmaceuticals. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.